Possible side effects with Korlym
It’s important to know what you may experience as your body gets used to less cortisol activity.
Clinical trial results
How Korlym® may help
Korlym is a once-daily oral treatment that has been shown to reduce certain negative effects of excess cortisol activity.
Korlym was studied in a 24-week clinical trial of 50 adults with endogenous Cushing syndrome who could not have surgery or for whom surgery had failed. All patients received Korlym. Korlym's effect on blood sugar was tested in 29 patients with type 2 diabetes or impaired blood sugar control.*
In patients with type 2 diabetes or impaired blood sugar control
60% (15/25) of patients saw at least a 25% improvement in their blood sugar levels. Some patients saw improvements in blood sugar within 6 weeks after starting treatment with Korlym
47% (7/15) of patients taking antidiabetic medicine had their medication reduced
Across the entire study group
Patients reported an overall decrease in depression symptoms†
Patients taking Korlym lost an average of 5.7% of their body weight after 6 months. On average, men (14 patients) lost 3.3 inches and women (32 patients) lost 2.7 inches from their waistline†
Patients were also assessed on 8 broad categories: glucose control, lipids, blood pressure, body composition, clinical appearance, strength, psychiatric symptoms, and quality of life.
†In the clinical study, some patients receiving Korlym reported changes in weight, waist measurement, appearance (such as the clearing of acne), mood, symptoms of depression, ability to think clearly, and muscle strength. It is uncertain whether Korlym caused these changes. At the start of the trial, patients had an average weight of 220 pounds and an average waistline of 47 inches.
